References
- Airaksinen M. M., Kari I. Beta‐carbolines, psychoactive compounds in the mammalian body. Part I: Occurrence, origin and metabolism. Med. Biol. 1981; 59(1)21–34, [PUBMED], [INFOTRIEVE]
- Anandatheerthavarada H. K., Shankar S. K., Ravindranath V. Rat brain cytochromes P450: catalytic, immunochemical properties and inducibility of multiple forms. Brain Res. 1990; 536: 339–343, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Anandatheerthavarada H. K., WIlliams J. F., Wecker L. The chronic administration of nicotine induces cytochrome P450 in rat brain. J. Neurochem. 1993a; 60(5)1941–1944, [PUBMED], [INFOTRIEVE]
- Anandatheerthavarada H. K., Williams J. F., Wecker L. Differential effect of chronic nicotine administration on brain cytochrome P4501A1/2 and P4502E1. Biochem. Biophys. Res. Commun. 1993b; 194(1)312–318, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Ariyoshi N., Miyazaki M., Toide K., Sawamura Y., Kamataki T. A single nucleotide polymorphism of CYP2b6 found in Japanese enhances catalytic activity by autoactivation. Biochem. Biophys. Res. Commun. 2001; 281(5)1256–1260, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Arthur H., Dahl M. L., Siwers B., Sjoqvist F. Polymorphic drug metabolism in schizophrenic patients with tardive dyskinesia. J. Clin. Psychopharmacol. 1995; 15(3)211–216, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Balfour D. J., Ridley D. L. The effects of nicotine on neural pathways implicated in depression: a factor in nicotine addiction?. Pharmacol. Biochem. Behav. 2000; 66(1)79–85, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Batel P., Pessione F., Maitre C., Rueff B. Relationship between alcohol and tobacco dependencies among alcoholics who smoke. Addiction 1995; 90(7)977–980, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Benedetti M. D., Bower J. H., Maraganore D. M., McDonnell S. K., Peterson B. J., Ahlskog J. E., Schaid D. J., Rocca W. A. Smoking, alcohol, and coffee consumption preceding Parkinson's disease: a case‐control study. Neurology 2000; 55(9)1350–1358, [PUBMED], [INFOTRIEVE], [CSA]
- Benowitz N. L., Peng M., Jacob P., III. Effects of cigarette smoking and carbon monoxide on chlorzoxazone and caffeine metabolism. Clin. Pharmacol. Ther. 2003; 74(5)468–474, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Bhagwat S. V., Boyd M. R., Ravindranath V. Multiple forms of cytochrome P450 and associated monooxygenase activities in human brain mitochondria. Biochem. Pharmacol. 2000; 59(5)573–582, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Bhamre S., Anandatheerathavarada H. K., Shankar S. K. Purification of multiple forms of cytochrome P450 from a human brain and reconstitution of catalitic activities. Arch. Biochem. Biophys. 1993; 301(2)251–255, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Blomqvist O., Ericson M., Johnson D. H., Engel J. A., Soderpalm B. Voluntary ethanol intake in the rat: effects of nicotinic acetylcholine receptor blockade or subchronic nicotine treatment. Eur. J. Pharmacol. 1996; 314(3)257–267, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Bordet R., Broly F., Destee A., Libersa C. Genetic polymorphism of cytochrome P450 2D6 in idiopathic Parkinson disease and diffuse Lewy body disease. Clin. Neuropharmacol. 1994; 17(5)484–488, [PUBMED], [INFOTRIEVE], [CSA]
- Boustead C., Taber H., Idle J. R., Cholerton S. CYP2D6 genotype and smoking behaviour in cigarette smokers. Pharmacogenetics 1997; 7(5)411–414, [PUBMED], [INFOTRIEVE], [CSA]
- Chen Z. R., Irvine R. J., Bodiner F., Somogy A. A. Morphine formation from codeine in rat brain: a possible mechanism of codeine analgesia. Life Sci. 1990; 46: 1067–1074, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Chew M., White J. M., Somogyi A. A., Bochner F., Irvine R. J. Precipitated withdrawal following codeine administration is dependent on CYP genotype. Eur. J. Pharmacol. 2001; 425(3)159–164, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Chinta S. J., Pai H. V., Upadhya S. C., Boyd M. R., Ravindranath V. Constitutive expression and localization of the major drug metabolizing enzyme, cytochrome P4502D in human brain. Brain Res. Mol. Brain Res. 2002; 103(1–2)49–61, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Chun J., Kent U. M., Moss R. M., Sayre L. M., Hollenberg P. F. Mechanism‐based inactivation of cytochromes P450 2B1 and P450 2B6 by 2‐phenyl‐2‐(1‐piperidinyl)propane. Drug Metab. Dispos. 2000; 28(8)905–911, [PUBMED], [INFOTRIEVE], [CSA]
- Code E. L., Crespi C. L., Penman B. W., Gonzalez F. J., Chang T. K., Waxman D. J. Human cytochrome P4502B6: interindividual hepatic expression, substrate specificity, and role in procarcinogen activation. Drug Metab. Dispos. 1997; 25(8)985–993, [PUBMED], [INFOTRIEVE], [CSA]
- Coleman T., Ellis S. W., Martin I. J., Lennard M. S., Tucker G. T. 1‐Methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP) is N‐demethylated by cytochromes P450 2D6, 1A2 and 3A4—implications for susceptibility to Parkinson's disease. J. Pharmacol. Exp. Ther. 1996; 277(2)685–690, [PUBMED], [INFOTRIEVE], [CSA]
- Crabb D. W. Ethanol oxidizing enzymes: roles in alcohol metabolism and alcoholic liver disease. Prog. Liver Dis. 1995; 13: 151–172, [PUBMED], [INFOTRIEVE], [CSA]
- Dahl A. R., Hadley W. M. Nasal cavity enzymes involved in xenobiotic metabolism: effects on the toxicity of inhalants. Crit. Rev. Toxicol. 1991; 21(5)345–372, [PUBMED], [INFOTRIEVE]
- Ding X., Kaminsky L. S. Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue‐selective chemical toxicity in the respiratory and gastrointestinal tracts. Annu. Rev. Pharmacol. Toxicol. 2003; 43: 149–173, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Ekins S., Wrighton S. A. The role of CYP2B6 in human xenobiotic metabolism. Drug Metab. Rev. 1999; 31(3)719–754, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Ekins S., Vandenbranden M., Ring B. J., Gillespie J. S., Yang T. J., Gelboin H. V., Wrighton S. A. Further characterization of the expression in liver and catalytic activity of CYP2B6. J. Pharmacol. Exp. Ther. 1998; 286(3)1253–1259, [PUBMED], [INFOTRIEVE], [CSA]
- Fadda F., Rossetti Z. L. Chronic ethanol consumption: from neuroadaptation to neurodegeneration. Prog. Neurobiol. 1998; 56(4)385–431, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Farin F. M., Omiecinski C. J. Regiospecific expression of cytochrome P‐450s and microsomal expoxide hydrolase in human brain tissue. J. Toxicol. Environ. Health 1993; 40(2–3)317–335, [PUBMED], [INFOTRIEVE]
- Fonne‐Pfister R., Bargetzi M. J., Meyer U. A. MPTP, the neurotoxin inducing Parkinson's disease, is a potent competitive inhibitor of human and rat cytochrome P450 isozymes (P450bufI, P450db1) catalyzing debrisoquine 4‐hydroxylation. Biochem. Biophys. Res. Commun. 1987; 148(3)1144–1150, [CSA]
- Fratiglioni L., Wang H. X. Smoking and Parkinson's and Alzheimer's disease: review of the epidemiological studies. Behav. Brain Res. 2000; 113(1–2)117–120, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Gervot L., Rochat B., Gautier J. C., Bohnenestengel F., Kroemer H., Berardinis V. D., Martin H., Beaune P., Waziers I. D. Human CYP2B6 expression, inducibility and catalytic activities. Pharmacogenetics 1999; 9: 295–306, [PUBMED], [INFOTRIEVE], [CSA]
- Ghersi‐Egea J. F., Perrin R., Leininger‐Muller B., Jeandel M. C.G.C.;, Floquet J., Cuny G., Siest G., Minn A. Subcellular localization of cytochrome P450, and activities of several enzymes responsible for drug metabolism in the human brain. Biochem. Pharmacol. 1993; 45(3)647–658, [CROSSREF], [CSA]
- Gilham D. E., Cairns W., Paine M. J.I., Modi S., Poulsom R., Roberts G. C.K., Wolf C. R. Metabolism of MPTP by cytochrome P4502D6 and the demonstration of 2D6 mRNA in human foetal and adult brain by in situ hybridization. Xenobiotica 1997; 27(1)111–125, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Hellmold H., Rylander T., Magnusson M., Reihner E., Warner M., Gustafsson J. A. Characterization of cytochrome P450 enzymes in human breast tissue from reduction mammaplasties. J. Clin. Endocrinol. Metab. 1998; 83(3)886–895, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Hesse L. M., Venkatakrishnan K., Court M. H., von Moltke L. L., Duan S. X., Shader R. I., Greenblatt D. J. CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. Drug Metab. Dispos. 2000; 28(10)1176–1183, [PUBMED], [INFOTRIEVE], [CSA]
- Hidestrand M., Oscarson M., Salonen J. S., Nyman L., Pelkonen O., Turpeinen M., Ingelman‐Sundberg M. CYP2B6 and CYP2C19 as the major enzymes responsible for the metabolism of selegiline, a drug used in the treatment of Parkinson's disease, as revealed from experiments with recombinant enzymes. Drug Metab. Dispos. 2001; 29(11)1480–1484, [PUBMED], [INFOTRIEVE], [CSA]
- Hiroi T., Imaoka S., Funae Y. Dopamine formation from tyramine by CYP2D6. Biochem. Biophys. Res. Commun. 1998; 249: 838–843, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Hiroi T., Kishimoto W., Chow T., Imaoka S., Igarashi T., Funae Y. Progesterone oxidation by cytochrome P450 2D isoforms in the brain. Endocrinology 2001; 142(9)3901–3908, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Hoffman S. M., Nelson D. R., Keeney D. S. Organization, structure and evolution of the CYP2 gene cluster on human chromosome 19. Pharmacogenetics 2001; 11(8)687–698, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Howard L. A., Sellers E. M., Tyndale R. F. The role of pharmacogenetically‐variable cytochrome P450 enzymes in drug abuse and dependence. Pharmacogenomics 2002; 3(2)185–199, [PUBMED], [INFOTRIEVE], [CSA]
- Howard L. A., Ahluwalia J. S., Lin S. K., Sellers E. M., Tyndale R. F. CYP2E1*1D regulatory polymorphism: association with alcohol and nicotine dependence. Pharmacogenetics 2003a; 13(6)321–328, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Howard L. A., Miksys S., Hoffmann E., Mash D., Tyndale R. F. Brain CYP2E1 is induced by nicotine and ethanol in rat and is higher in smokers and alcoholics. Br. J. Pharmacol. 2003b; 138(7)1376–1386, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- http://www.imm.ki.se/CYPalleles/cyp2b6.htm (accessed December 2003).
- http://www.imm.ki.se/CYPalleles/cyp2d6.htm (accessed December 2003).
- http://www.imm.ki.se/CYPalleles/cyp2e1.htm (accessed December 2003).
- Huang Z., Roy P., Waxman D. J. Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N‐dechloroethylation of cyclophosphamide and ifosfamide. Biochem. Pharmacol. 2000; 59(8)961–972, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Hukkanen J., Pelkonen O., Hakkola J., Raunio H. Expression and regulation of xenobiotic‐metabolizing cytochrome P450 (CYP) enzymes in human lung. Crit. Rev. Toxicol. 2002; 32(5)391–411, [PUBMED], [INFOTRIEVE], [CSA]
- Ingelman‐Sundberg M. Polymorphism of cytochrome P450 and xenobiotic toxicity. Toxicology 2002; 181–182: 447–452, [CROSSREF]
- Jacob P., III, Ulgen M., Gorrod J. W. Metabolism of (−)‐(S)‐nicotine by guinea pig and rat brain: identification of cotinine. Eur. J. Drug Metab. Pharmacokitet. 1997; 22(4)391–394
- Janmohamed A., Dolphin C. T., Phillips I. R., Shephard E. A. Quantification and cellular localization of expression in human skin of genes encoding flavin‐containing monooxygenases and cytochromes P450. Biochem. Pharmacol. 2001; 62(6)777–786, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Jinno H., Tanaka‐Kagawa T., Ohno A., Makino Y., Matsushima E., Hanioka N., Ando M. Functional characterization of cytochrome P450 2B6 allelic variants. Drug Metab. Dispos. 2003; 31(4)398–403, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Jolivalt C., Minn A., Vincent‐Viry M., Galteau M. ‐M., Siest G. Dextromethorphan O‐demethylase activity in rat brain microsomes. Neurosci. Lett. 1995; 187: 65–68, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Kathiramalainathan K., Kaplan H. L., Romach M. K., Busto U. E., Li N. Y., Sawe J., Tyndale R. F., Sellers E. M. Inhibition of cytochrome P450 2D6 modifies codeine abuse liability. J. Clin. Psychopharmacol. 2000; 20(4)435–444, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Kempermann G., Knoth R., Gebicke‐Haerter P. J., Stolz B. J., Volk B. Cytochrome P450 in rat astrocytes in vivo and in vitro: intracellular localization and induction by phenytoin. J. Neurosci. Res. 1994; 39(5)576–588, [PUBMED], [INFOTRIEVE], [CSA]
- Kirchheiner J., Klein C., Meineke I., Sasse J., Zanger U. M., Murdter T. E., Roots I., Brockmoller J. Bupropion and 4‐OH‐bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6. Pharmacogenetics 2003; 13(10)619–626, [PUBMED], [INFOTRIEVE], [CSA]
- Kishimoto W., Hiroi T., Shiraishi M., Osada M., Imaoka S., Kominami S., Igarashi T., Funai Y. Cytochrome P450 2D catalyze steroid 21‐hydroxylation in the brain. Endocrinology 2003; 145(2)699–705, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Kopun M., Propping P. The kinetics of ethanol absorption and elimination in twins and supplementary repetitive experiments in singleton subjects. Eur. J. Clin. Pharmacol. 1977; 11(5)337–344, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Kreth K., Kovar K., Schwab M., Zanger U. M. Identification of the human cytochromes P450 involved in the oxidative metabolism of “Ecstasy”‐related designer drugs. Biochem. Pharmacol. 2000; 59(12)1563–1571, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Kumagai Y., Lin L. Y., Hiratsuka A., Narimatsu S., Suzuki T., Yamada H., Oguri K., Yoshimura H., Cho A. K. Participation of cytochrome P450‐2B and ‐2D isozymes in the demethylenation of methylenedioxymethamphetamine enantiomers by rats. Mol. Pharmacol. 1994; 45(2)359–365, [PUBMED], [INFOTRIEVE], [CSA]
- Kurth M. C., Kurth J. H. Variant cytochrome P450 CYP2D6 allelic frequencies in Parkinson's disease. Am. J. Med. Genet. 1993; 48(3)166–168, [PUBMED], [INFOTRIEVE]
- Lamba V., Lamba J., Yasuda K., Strom S., Davila J., Hancock M. L., Fackenthal J. D., Rogan P. K., Ring B., Wrighton S. A., Schuetz E. G. Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression. J. Pharmacol. Exp. Ther. 2003; 307(3)906–922, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Lang T., Klein K., Fischer J., Nussler A. K., Neuhaus P., Hofmann U., Eichelbaum M., Schwab M., Zanger U. M. Extensive genetic polymophism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics 2001; 11: 399–415, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Lee M., Wrensch M., Miike R. Dietary and tobacco risk factors for adult onset glioma in the San Francisco Bay Area (California, USA). Cancer Causes Control 1997; 8(1)13–24, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Lieber C. S. Cytochrome P‐4502E1: its physiological and pathological role. Physiol. Rev. 1997; 77(2)517–544, [PUBMED], [INFOTRIEVE], [CSA]
- Lieber C. S. Microsomal ethanol‐oxidizing system (MEOS): the first 30 years (1968–1998)—a review. Alcohol., Clin. Exp. Res. 1999; 23(6)991–1007, [CSA]
- Lin L. Y., Kumagai Y., Cho A. K. Enzymatic and chemical demethylenation of (methylenedioxy)amphetamine and (methylenedioxy)methamphetamine by rat brain microsomes. Chem. Res. Toxicol. 1992; 5: 401–406, [PUBMED], [INFOTRIEVE]
- Llerena A., Edman G., Cobaleda J., Benitez J., Schalling D., Bertilsson L. Relationship between personality and debrisoquine hydroxylation capacity. Suggestion of an endogenous neuroactive substrate or product of the cytochrome P4502D6. Acta Psychiatr. Scand. 1993; 87(1)23–28, [PUBMED], [INFOTRIEVE]
- Llerena A., Cobaleda J., Martinez C., Benitez J. Interethnic differences in drug metabolism: influence of genetic and environmental factors on debrisoquine hydroxylation phenotype. Eur. J. Drug Metab. Pharmacokinet. 1996; 21(2)129–138, [PUBMED], [INFOTRIEVE], [CSA]
- Loeper J., Descatoire V., Maurice M., Beaune P., Belghiti J., Houssin D., Ballet F., Feldmann G., Guengerich F. P., Pessayre D. Cytochromes P‐450 in human hepatocyte plasma membrane: recognition by several autoantibodies. Gastroenterology 1993; 104(1)203–216, [PUBMED], [INFOTRIEVE]
- Lundqvist C., Alling C., Knoth R., Volk B. Intermittent ethanol exposure of adult rats: hippocampal cell loss after one month of treatment. Alcohol Alcohol. 1995; 30(6)737–748, [PUBMED], [INFOTRIEVE]
- McFadyen M. C.E., Melvin W. T., Murray G. I. Regional distribution of individual forms of cytochrome P450 mRNA in normal adult human brain. Biochem. Pharmacol. 1998; 55: 825–830, [CROSSREF], [CSA]
- Melchior C., Collins M. A. The route and significance of endogenous synthesis of alkaloids in animals. Crit. Rev. Toxicol. 1982; 9(4)313–356, [PUBMED], [INFOTRIEVE]
- Messina E. S., Tyndale R. F., Sellers E. M. A major role for CYP2A6 in nicotine C‐oxidation by human liver microsomes. J. Pharmacol. Exp. Ther. 1997; 282(3)1608–1614, [PUBMED], [INFOTRIEVE], [CSA]
- Meyer U. A., Skoda R. C., Zanger U. M. The genetic polymorphism of debrisoquine/sparteine metabolism—molecular mechanisms. Pharmacol. Ther. 1990; 46: 297–308, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Miksys S. L., Tyndale R. F. Drug‐metabolizing cytochrome P450s in the brain. J. Psychiatry Neurosci. 2002; 27(6)406–415, [PUBMED], [INFOTRIEVE], [CSA]
- Miksys S., Rao Y., M.Sellers E., Kwan M., Mendis D., F.Tyndale R. Regional and cellular distribution of CYP2D subfamily members in rat brain. Xenobiotica 2000a; 30(6)547–564, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Miksys S., Hoffmann E., Tyndale R. F. Regional and cellular induction of nicotine‐metabolizing CYP2B1 in rat brain by chronic nicotine treatment. Biochem. Pharmacol. 2000b; 59: 1501–1511, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Miksys S., Rao Y., Hoffmann E., Mash D. C., Tyndale R. F. Regional and cellular expression of CYP2D6 in human brain: higher levels in alcoholics. J. Neurochem. 2002; 82(6)1376–1387, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Miksys S., Lerman C., Shields P. G., Mash D. C., Tyndale R. F. Smoking, alcoholism and genetic polymorphisms alter CYP2B6 levels in human brain. Neuropharmacology 2003; 45(1)122–132, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Miller G. P., Hanna I. H., Nishimura Y., Guengerich F. P. Oxidation of phenethylamine derivatives by cytochrome P450 2D6: the issue of substrate protonation in binding and catalysis. Biochemistry 2001; 40(47)14215–14223, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Montoliu C., Valles S., Renau‐Piqueras J., Guerri C. Ethanol‐induced oxygen radical formation and lipid peroxidation in rat brain: effect of chronic alcohol consumption. J. Neurochem. 1994; 63(5)1855–1862, [PUBMED], [INFOTRIEVE]
- Montoliu C., Sancho‐Tello M., Azorin I., Burgal M., Valles S., Renau‐Piqueras J., Guerri C. Ethanol increases cytochrome P4502E1 and induces oxidative stress in astrocytes. J. Neurochem. 1995; 65(6)2561–2570, [PUBMED], [INFOTRIEVE]
- Muskhelishvili L., Thompson P. A., Kusewitt D. F., Wang C., Kadlubar F. F. In situ hybridization and immunohistochemical analysis of cytochrome P450 1B1 expression in human normal tissues. J. Histochem. Cytochem. 2001; 49(2)229–236, [PUBMED], [INFOTRIEVE], [CSA]
- Mutch E., Blain P. G., Williams F. M. The role of metabolism in determining susceptibility to parathion toxicity in man. Toxicol. Lett. 1999; 107(1–3)177–187, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Nakayama H., Okuda H., Nakashima T., Imaoka S., Funae Y. Nicotine metabolism by rat hepatic cytochrome P450s. Biochem. Pharmacol. 1993; 45(12)2554–2556, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Neve E. P.A., Eliasson E., Pronzato M. A., Albano E., Marinari U., Ingelman‐Sundberg M. Enzyme‐specific transport of rat liver cytochrome P450 to the Golgi apparatus. Arch. Biochem. Biophys. 1996; 333(2)459–465, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Nissbrandt H., Bergquist F., Jonason J., Engberg F. Inhibition of cytochrome P450 2E1 induces an increase in extracellular dopamine in rat substanti nigra: a new metabolic pathway?. Synapse 2001; 40: 294–301, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Norris P. J., Hardwick J. P., Emson P. C. Regional distribution of cytochrome P450 2D1 in the rat central nervous system. J. Comp. Neurol. 1996; 366: 244–258, [PUBMED], [INFOTRIEVE], [CSA]
- Oda Y., Hamaoka N., Hiroi T., Imaoka S., Hase I., Tanaka K., Funae Y., Ishizaki T., Asada A. Involvement of human liver cytochrome P4502B6 in the metabolism of propofol. Br. J. Clin. Pharmacol. 2001; 51(3)281–285, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Ohe T., Hirobe M., Mashino T. Novel metabolic pathway of estrone and 17beta‐estradiol catalyzed by cytochrome P‐450. Drug Metab. Dispos. 2000; 28(2)110–112, [PUBMED], [INFOTRIEVE], [CSA]
- Ohmori O., Suzuki T., Kojima H., Shinkai T., Terao T., Mita T., Abe K. Tardive dyskinesia and debrisoquine 4‐hydroxylase (CYP2D6) genotype in Japanese schizophrenics. Schizophr. Res. 1998; 32(2)107–113, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Parkinson A. Biotransformation of xenobiotics. Casarett and Doull's Toxicology; The Basic Science of Poisons6th ed., C. D. Klasson. The McGraw‐Hill Companies, New York 2001; 133–224
- Pasanen M., Pelkonen O. The expression and environmental regulation of P450 enzymes in human placenta. Crit. Rev. Toxicol. 1994; 24(3)211–229, [PUBMED], [INFOTRIEVE], [CSA]
- Pascussi J. M., Gerbal‐Chaloin S., Drocourt L., Maurel P., Vilarem M. J. The expression of CYP2B6, CYP2C9 and CYP3A4 genes: a tangle of networks of nuclear and steroid receptors. Biochim. Biophys. Acta 2003; 1619(3)243–253, [PUBMED], [INFOTRIEVE]
- Pellinen P., Kulmala L., Konttila J., Auriola S., Pasanen M., Juvonen R. Kinetic characteristics of norcocaine N‐hydroxylation in mouse and human liver microsomes: involvement of CYP enzymes. Arch. Toxicol. 2000; 74(9)511–520, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Poirier M. F., Canceil O., Bayle F., Millet B., Bourdel M. C., Moatti C., Olie J. P., Attar‐Levy D. Prevalence of smoking in psychiatric patients. Prog. Neuro‐psychopharmacol. Biol. Psychiatry 2002; 26(3)529–537, [CROSSREF]
- Richmond R., Zwar N. Review of bupropion for smoking cessation. Drug Alochol Rev. 2003; 22(2)203–220, [CROSSREF]
- Riedl A. G., Watts P. M., Jenner P., Marsden C. D. P450 enzymes and Parkinson's disease: the story so far. Mov. Disord. 1998; 13(2)212–220, [PUBMED], [INFOTRIEVE], [CSA]
- Riley J. N., Walker D. W. Morphological alterations in hippocampus after long‐term alcohol consumption in mice. Science 1978; 201(4356)646–648, [PUBMED], [INFOTRIEVE]
- Rosenbrock H., Hagemeyer C. E., Singec I., Knoth R., Volk B. Testosterone metabolism in rat brain is differentially enhanced by phentoin‐inducible cytochrome P450 isoforms. J. Neuroendocrinol. 1999; 11(8)597–604, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Rosenbrock H., Hagemeyer C. E., Ditter M., Knoth R., Volk B. Expression and localization of the CYP2B subfamily predominantly in neurones of rat brain. J. Neurochem. 2001; 76: 332–340, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Roy A., DeJong J., Lamparski D., George T., Linnoila M. Depression among alcoholics. Relationship to clinical and cerebrospinal fluid variables. Arch. Gen. Psychiatry 1991; 48(5)428–432, [PUBMED], [INFOTRIEVE]
- Saarikoski S. T., Sata F., Husgafvel‐Pursiainen K., Rautalahti M., Haukka J., Impivaara O., Jarvisalo J., Vainio H., Hirvonen A. CYP2D6 ultrarapid metabolizer genotype as a potential modifier of smoking behaviour. Pharmacogenetics 2000; 10(1)5–10, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Saitoh T., Xia Y., Chen X., Masliah E., Galasko D., Shults C., Thal L. J., Hansen L. A., Katzman R. The CYP2D6B mutant allele is overrepresented in the Lewy body variant of Alzheimer's disease. Ann. Neurol. 1995; 37(1)110–112, [PUBMED], [INFOTRIEVE], [CSA]
- Salonen J. S., Nyman L., Boobis A. R., Edwards R. J., Watts P., Lake B. G., Price R. J., Renwick A. B., Gomez‐Lechon M. J., Castell J. V., Ingelman‐Sundberg M., Hidestrand M., Guillouzo A., Corcos L., Goldfarb P. S., Lewis D. F., Taavitsainen P., Pelkonen O. Comparative studies on the cytochrome p450‐associated metabolism and interaction potential of selegiline between human liver‐derived in vitro systems. Drug Metab. Dispos. 2003; 31(9)1093–1102, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Schilter B., Anderson M. R., Acharya C., Omiecinski C. J. Activation of cytochrome P450 gene expression in the rat brain by phenobarbital‐like inducers. J. Pharmacol. Exp. Ther. 2000; 294: 916–922, [PUBMED], [INFOTRIEVE], [CSA]
- Schoedel K. A., Sellers E. M., Tyndale R. F. Induction of CYP2B1/2 and nicotine metabolism by ethanol in rat liver but not rat brain. Biochem. Pharmacol. 2001; 62(8)1025–1036, [PUBMED], [INFOTRIEVE], [CSA]
- Schoedel K. A., Tyndale R. F. Induction of nicotine‐metabolizing CYP2B1 by ethanol and ethanol‐metabolizing CYP2E1 by nicotine: summary and implications. Biochim. Biophys. Acta 2003; 1619(3)283–290, [PUBMED], [INFOTRIEVE]
- Schoedel K. A., Sellers E. M., Palmour R., Tyndale R. F. Down‐regulation of hepatic nicotine metabolism and a CYP2A6‐like enzyme in African green monkeys after long‐term nicotine administration. Mol. Pharmacol. 2003; 63(1)96–104, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Siegle I., Fritz P., Eckhardt K., Zanger U. M., Eichelbaum M. Cellular localization and regional distribution of CYP2D6 mRNA and protein expression in human brain. Pharmacogenetics 2001; 11: 237–245, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Sohda T., Shimizu M., Kamimura S., Okumura M. Immunohistochemical demonstration of ethanol‐inducible P450 2E1 in rat brain. Alcohol Alcohol. 1993; 28: 69–75
- Strobel H. W., Thompson C. M., Antonovic L. Cytochrome P450 in brain: function and significance. Curr. Drug Metab. 2001; 2(2)199–214, [PUBMED], [INFOTRIEVE]
- Tanaka S., Chen X., Xia Y., Kang D. E., Matoh N., Sundsmo M., Thomas R. G., Katzman R., Thal L. J., Trojanowski J. Q., Saitoh T., Ueda K., Masliah E. Association of CYP2D microsatellite polymorphism with Lewy body variant of Alzheimer's disease. Neurology 1998; 50(6)1556–1562, [PUBMED], [INFOTRIEVE], [CSA]
- Tindberg N., Ingelman‐Sundberg M. Expression, catalytic activity, and inducibility of cytochrome P450 2E1 (CYP2E1) in the rat central nervous system. J. Neurochem. 1996; 67(5)2066–2073, [PUBMED], [INFOTRIEVE]
- Torvik A., Torp S. The prevalence of alcoholic cerebellar atrophy. A morphometric and histological study of an autopsy material. J. Neurol. Sci. 1986; 75(1)43–51, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Tredaniel J., Boffetta P., Saracci R., Hirsch A. Environmental tobacco smoke and the risk of cancer in adults. Eur. J. Cancer 1993; 14: 2058–2068, [CROSSREF]
- Tyndale R. F. Genetics of alcohol and tobacco use in humans. Ann. Med. 2003; 35(2)94–121, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Tyndale R. F., Sunahara R., Inaba T., Kalow W., Gonzalez F. J., Niznik H. B. Neuronal cytochrome P450IID1 (debrisoquine/sparteine‐type): potent inhibition of activity by (−)‐cocaine and nucleotide sequence identity to human hepatic P450 gene CYP2D6. Mol. Pharmacol. 1991; 40: 63–68, [PUBMED], [INFOTRIEVE], [CSA]
- Tyndale R. F., Li Y., Li N. ‐Y., Messina E., Miksys S., Sellers E. M. Characterization of cytochrome P‐450 2D1 activity in rat brain; high‐affinity kinetics for dextromethorphan. Drug Metab. Dispos. 1999; 27(8)924–930, [PUBMED], [INFOTRIEVE], [CSA]
- Upadhya S. C., Tirumalai P. S., Boyd M. R., Mori T., Ravindranath V. Cytochrome P4502E (CYP2E) in brain: constitutive expression, induction by ethanol and localization by fluorescence in situ hybridization. Arch. Biochem. Biophys. 2000; 373(1)23–34, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Villard P. H., Seree E. M., Re J. L., De Meo M., Barra Y., Attolini L., Dumenil G., Catalin J., Durand A., Lacarelle B. Effects of tobacco smoke on the gene expression of the Cyp1a, Cyp2b, Cyp2e, and Cyp3a subfamilies in mouse liver and lung: relation to single strand breaks of DNA. Toxicol. Appl. Pharmacol. 1998; 148(2)195–204, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Vincent‐Viry M., Fournier B., Galteau M.‐M. The effects of drinking and smoking on the CYP2D6 metabolic capacity. Drug Metab. Dispos. 2000; 28: 617–619, [CSA]
- Volk B., Meyer R. P., Lintig F. v., Ibach B., Knoth R. Localization and characterization of cytochrome P450 in the brain. In vivo and in vitro investigations on phenytoin‐ and phenobarbital‐inducible forms. Toxicol. Lett. 1995; 82/83(655–622)
- Wadelius M., Darj E., Frenne G., Rane A. Induction of CYP2D6 in pregnancy. Clin. Pharmacol. Ther. 1997; 62(4)400–407, [PUBMED], [INFOTRIEVE], [CSA]
- Warner M., Gustafsson J. A. Effect of ethanol on cytochrome P450 in the rat brain. Proc. Natl. Acad. Sci. U. S. A. 1994; 91(3)1019–1023, [PUBMED], [INFOTRIEVE], [CSA]
- Warner M., Hellmold H., Yoshida S., Liao D., Hedlund E., Gustafsson J. A. Cytochrome P450 in the breast and brain: role in tissue‐specific activation of xenobiotics. Mutat. Res. 1997; 376(1–2)79–85, [PUBMED], [INFOTRIEVE]
- Woodcroft K. J., Novak R. F. Xenobiotic‐enhanced expression of cytochromes P450 2E1 and 2B in primary cultured rat hepatocytes. Drug Metab. Dispos. 1998; 26(4)372–378, [PUBMED], [INFOTRIEVE], [CSA]
- Wu D., Cederbaum A. I. Presence of functionally active cytochrome P‐450IIEI in the plasma membrane of rat hepatocytes. Hepatology 1992; 15(3)515–524, [PUBMED], [INFOTRIEVE]
- Yamazaki H., Inoue K., Hashimoto M., Shimada T. Roles of CYP2A6 and CYP2B6 in nicotine C‐oxidation by human liver microsomes. Arch. Toxicol. 1999; 73(2)65–70, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Yanagihara Y., Kariya S., Ohtani M., Uchino K., Aoyama T., Yamamura Y., Iga T. Involvement of CYP2B6 in n‐demethylation of ketamine in human liver microsomes. Drug Metab. Dispos. 2001; 29(6)887–890, [PUBMED], [INFOTRIEVE], [CSA]
- Yengi L. G., Xiang Q., Pan J., Scatina J., Kao J., Ball S. E., Fruncillo R., Ferron G., Roland Wolf C. Quantitation of cytochrome P450 mRNA levels in human skin. Anal. Biochem. 2003; 316(1)103–110, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Yu A. M., Idle J. R., Herraiz T., Kupfer A., Gonzalez F. J. Screening for endogenous substrates reveals that CYP2D6 is a 5‐methoxyindolethylamine O‐demethylase. Pharmacogenetics 2003a; 13(6)307–319, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Yu A. M., Idle J. R., Byrd L. G., Krausz K. W., Kupfer A., Gonzalez F. J. Regeneration of serotonin from 5‐methoxytryptamine by polymorphic human CYP2D6. Pharmacogenetics 2003b; 13(3)173–181, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Yu A. M., Idle J. R., Krausz K. W., Kupfer A., Gonzalez F. J. Contribution of individual cytochrome P450 isozymes to the O‐demethylation of the psychotropic beta‐carboline alkaloids harmaline and harmine. J. Pharmacol. Exp. Ther. 2003c; 305(1)315–322, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Zanger U. M., Raimundo S., Eichelbaum M. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn‐Schmiedeberg's Arch. Pharmacol. 2004; 369(1)23–37, [CROSSREF], [CSA]
- Zhang Y., Benet L. Z. The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P‐glycoprotein. Clin. Pharmacokinet. 2001; 40(3)159–168, [PUBMED], [INFOTRIEVE], [CSA]
- Zhukov A., Ingelman‐Sundberg M. Relationship between cytochrome P450 catalytic cycling and stability: fast degradation of ethanol‐inducible cytochrome P450 2E1 (CYP2E1) in hepatoma cells is abolished by inactivation of its electron donor NADPH‐cytochrome P450 reductase. Biochem. J. 1999; 340(Pt. 2)453–458, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Zimatkin S. M., Liopo A. V., Deitrich R. A. Distribution and kinetics of ethanol metabolism in rat brain. Alcohol., Clin. Exp. Res. 1998; 22(8)1623–1627